Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure
Takayoshi Tsutamoto, MDa,
Atsuyuki Wada, MDa,
Keiko Maeda, MDa,
Naoko Mabuchi, MDa,
Masaru Hayashi, MDa,
Takashi Tsutsui, MDa,
Masato Ohnishi, MDa,
Masahide Sawaki, MDa,
Masanori Fujii, MDa,
Takehiro Matsumoto, MDa,
Toshiki Matsui, MDa and
Masahiko Kinoshita, MDa
a First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan
View larger version (14K):
[in a new window]
|
Figure 1 Absolute changes from the baseline in left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI) and left ventricular mass index (LVMI) before and after treatment with placebo or spironolactone for four months in patients with mild-to-moderate congestive heart failure. *p < 0.05; **p < 0.01 versus placebo.
|
|
View larger version (13K):
[in a new window]
|
Figure 2 Absolute changes from the baseline in plasma levels of aldosterone (ALD), brain natriuretic peptide (BNP), and procollagen type III aminoterminal peptide (PIIINP) before and after treatment with placebo or spironolactone for four months in patients with mild-to-moderate congestive heart failure. *p < 0.05; **p < 0.01 versus placebo.
|
|
View larger version (21K):
[in a new window]
|
Figure 3 Correlation between the changes of procollagen type III aminoterminal peptide (PIIINP) and left ventricular mass index (LVMI) after four months of spironolactone treatment in 20 patients with mild-to-moderate congestive heart failure. Delta PIIINP = pretreatment value of PIIINP – the value of PIIINP after four months, delta LVMI = pretreatment value of LVMI – the value of LVMI after four months.
|
|
|
